De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Atrys Health Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Isabel Lozano Fernandez

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	1.5yrs

Recente managementupdates

Recent updates

Atrys Health, S.A. (BME:ATRY) Shares Could Be 33% Above Their Intrinsic Value Estimate

Dec 11

CEO

Isabel Lozano Fernandez

no data

Tenure

Ms. Isabel Lozano Fernandez serves as Chief Executive Officer and Executive Director at Atrys Health, S.A. Ms. Lozano Fernández served as Chief Executive Officer and Managing Director of PharmaMar, SA. Ms....

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Santiago De Torres Sanahuja	Executive Chairman	no data	geen gegevens	0.18% € 466.6k
Isabel Lozano Fernandez	CEO & Executive Director	no data	geen gegevens	0.44% € 1.1m
Antonio Baselga de la Vega	Director	no data	geen gegevens	geen gegevens
Josep Echarri Torres	Director	no data	geen gegevens	geen gegevens
Jaime Cano Fernandez	Independent Director	no data	geen gegevens	0.030% € 77.8k
Jaime del Barrio Seoane	Independent Director	no data	geen gegevens	0.030% € 77.8k
Fernando de Lorenzo Lopez	Director	no data	geen gegevens	geen gegevens
Francisco Jose Navarro	Proprietary Director	less than a year	geen gegevens	geen gegevens
Anabel Porta	Proprietary Director	2.8yrs	geen gegevens	geen gegevens
Manuel Maldonado	Proprietary Director	1.8yrs	geen gegevens	geen gegevens
Gonzalez Miriam	Independent Director	1.3yrs	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van ATRY wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw bestuur.

Atrys Health Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Consensus EPS estimates fall by 22%

Atrys Health, S.A.'s (BME:ATRY) 38% Share Price Surge Not Quite Adding Up

Full year 2023 earnings released: €0.60 loss per share (vs €0.34 loss in FY 2022)

Consensus EPS estimates fall by 65%

Consensus EPS estimates fall by 25%

New minor risk - Share price stability

Now 23% undervalued after recent price drop

Arraigo Midco Sl acquired a 75% stake in Professional Group Conversia, S.L.U from Atrys Health, S.A. (BME:ATRY) for €35 million.

Price target decreased by 8.4% to €7.23

First half 2023 earnings released: €0.17 loss per share (vs €0.044 loss in 1H 2022)

New minor risk - Financial position

Is Atrys Health, S.A. (BME:ATRY) Trading At A 44% Discount?

New minor risk - Share price stability

The Returns At Atrys Health (BME:ATRY) Aren't Growing

Price target decreased by 15% to €8.85

Full year 2022 earnings released: €0.34 loss per share (vs €0.46 loss in FY 2021)

Atrys Health, S.A. acquired 70% stake in Initia Research.

Atrys Health, S.A. (BME:ATRY) acquired ChileRad for €10 million.

Returns On Capital Are Showing Encouraging Signs At Atrys Health (BME:ATRY)

Less than half of directors are independent

Price target decreased to €10.46

First half 2022 earnings released: EPS: €0 (vs €0.084 loss in 1H 2021)

Juan María Riberas Mera acquired a 5.432% stake in Atrys Health, S.A. (BME:ATRY) for €28 million.

Atrys Health, S.A. (BME:ATRY) agreed to acquire Significant Impact Systems SL for €94.47 million.

Less than half of directors are independent

Full year 2021 earnings: Revenues miss analyst expectations

Now 21% undervalued after recent price drop

Atrys Health (BME:ATRY) Might Have The Makings Of A Multi-Bagger

Price target increased to €11.39

Atrys Health, S.A. (BME:ATRY) signed an agreement to acquire Genetyca.

An unknown buyer acquired 5% stake in Atrys Health, S.A. (BME:ATRY) from Inversiones Industriales Serpis S.L.

Price target raised to €10.18

Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America

Did You Miss Atrys Health's (BME:ATRY) Whopping 387% Share Price Gain?

New 90-day high: €10.20

New 90-day high: €8.90

Atrys Health, S.A. (BME:ATRY) Shares Could Be 33% Above Their Intrinsic Value Estimate

Atrys Health, S.A. (BME:ATRY) acquired 91.7% stake in Grupo Lenitudes SGPS, SA from MCH Iberian Capital Fund III, FCR managed by MCH for €19.6 million.

New 90-day high: €7.86

Atrys Health, S.A. (BME:ATRY) acquired Instituto de Estudios Celulares y Moleulares S.A.

Atrys Health, S.A. (BME:ATRY) acquired Axismed Gestão Preventiva da Saúde S.A. from Telefónica Digital España, S.L. for BRL 14 million.

Atrys Health, S.A. announced that it has received €35.2 million in funding

CEO

Tenure

Bestuursleden

Gemiddelde duur